These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20098798)

  • 1. [Risk of type 2 diabetes mellitus among users of atypical antipsychotic drugs or conventional treatment: systematic review and meta-analysis].
    Sapunar Z J; Muñoz N S; Vásquez A T
    Rev Med Chil; 2009 Nov; 137(11):1417-26. PubMed ID: 20098798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
    Feldman PD; Hay LK; Deberdt W; Kennedy JS; Hutchins DS; Hay DP; Hardy TA; Hoffmann VP; Hornbuckle K; Breier A
    J Am Med Dir Assoc; 2004; 5(1):38-46. PubMed ID: 14706127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
    Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
    Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
    Mosolov SN; Kabanov SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
    [No Abstract]   [Full Text] [Related]  

  • 5. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatic tolerance of atypical antipsychotic drugs].
    Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose intolerance with atypical antipsychotics.
    Hedenmalm K; Hägg S; Ståhl M; Mortimer O; Spigset O
    Drug Saf; 2002; 25(15):1107-16. PubMed ID: 12452735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical antipsychotic prescribing and diabetes.
    Agius M; Murphy CL; Win A; Zaman R
    Psychiatr Danub; 2007 Jun; 19(1-2):89-90. PubMed ID: 17603422
    [No Abstract]   [Full Text] [Related]  

  • 9. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
    Ollendorf DA; Joyce AT; Rucker M
    MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The implications of weight changes with antipsychotic treatment.
    Sussman N
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative safety of antipsychotics: another look at the risk of diabetes.
    Moisan J; Turgeon M; Desjardins O; Grégoire JP
    Can J Psychiatry; 2013 Apr; 58(4):218-24. PubMed ID: 23547645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.
    Hägg S; Joelsson L; Mjörndal T; Spigset O; Oja G; Dahlqvist R
    J Clin Psychiatry; 1998 Jun; 59(6):294-9. PubMed ID: 9671341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.
    Ramaswamy K; Masand PS; Nasrallah HA
    Ann Clin Psychiatry; 2006; 18(3):183-94. PubMed ID: 16923657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
    Leslie DL; Rosenheck RA
    Am J Psychiatry; 2004 Sep; 161(9):1709-11. PubMed ID: 15337666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.
    Bou Khalil R
    Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes resolution following discontinuation of a second-generation antipsychotic.
    Strassnig M; Awerbuck J; Ganguli R
    Clin Schizophr Relat Psychoses; 2013 Jan; 6(4):202-3. PubMed ID: 23302450
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic effects of the atypical antipsychotics.
    Wooten J
    South Med J; 2007 Aug; 100(8):771-2. PubMed ID: 17713300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.